

MARKET REPORT



Ulcerative Colitis Market by Molecule Type (Biologics and Small Molecules), by Disease Type (Mild Ulcerative Colitis, Moderate Ulcerative Colitis, Severe Ulcerative Colitis), by Route of Administration (Oral and Injectables) - Global Opportunity Analysis and Industry Forecast, 2017-2023

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Ulcerative Colitis Market by Molecule Type (Biologics and Small Molecules), by Disease Type (Mild Ulcerative Colitis, Moderate Ulcerative Colitis, Severe Ulcerative Colitis), by Route of Administration (Oral and Injectables) - Global Opportunity Analysis and Industry Forecast, 2017-2023

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** bioportfolio97@gmail.com

Ulcerative Colitis Market by Molecule Type (Biologics and Small Molecules), by Disease Type (Mild Ulcerative Colitis, Moderate Ulcerative Colitis, Severe Ulcerative Colitis), by Route of Administration (Oral and Injectables) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Ulcerative colitis (UC) is an inflammatory gastrointestinal disease that affects colon or large intestine. UC is characterized as an incurable disease with low mortality rate and is generally diagnosed in adolescence and early adulthood. As per NCBI, about 1.86 billion patients were diagnosed with UC globally in 2014, with 1.54 billion patients currently receiving treatment. Moreover, it is estimated that in 2015, there were 2.1 million diagnosed cases of UC in U.S., Japan, and five major European countries namely Germany, France, Italy, Spain, and UK. The global ulcerative colitis market accounted for \$4,785 million in 2016 and is expected to reach \$7,455 million by 2023, registering a CAGR of 6.5% from 2017 to 2023.

The major factors that drive the growth of the global ulcerative colitis market are increasing number of ulcerative colitis patients, new drug formulations by key players, and increasing investments by government and non-government organizations towards research in biologics. However, patent expiry and availability of alternative surgery option for UC treatment restricts the market growth. Conversely, untapped economies are expected to provide lucrative growth opportunities to the market.

The report segments the global ulcerative colitis market based on disease type, molecule type, and route of administration. Based on molecule type, the market is categorized as biologics and small molecules. In terms of disease type, the market is divided into mild, moderate, and severe ulcerative colitis. Based on route of administration, the market is bifurcated into oral and injectables. Regionally, the market is analyzed in North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS:

This report provides an extensive analysis of the current and emerging market trends and dynamics in the global ulcerative colitis market.

Comprehensive analysis of all geographic regions is provided to determine the prevailing opportunities across the geographies.

This report entails the detailed quantitative analysis of the current market and estimations from 2016 to 2023 to identify the prevailing opportunities.

Comprehensive analysis of factors that drive and restrict the market growth is provided in the report.

Region- and country-wise ulcerative colitis market conditions are comprehensively analyzed in the report.

KEY MARKET SEGMENTS

By Disease Type

Mild Ulcerative Colitis

Moderate Ulcerative Colitis

Severe Ulcerative Colitis

By Molecule Type

Biologics

Small Molecules

By Route of Administration

Oral

Injectables

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

UK

Italy

Spain

Rest of Europe

Asia-Pacific

Japan

China

Australia

South Korea

India

Rest of Asia-Pacific

LAMEA

Saudi Arabia

South Africa

Israel

Rest of LAMEA

Additional Details

Publisher : Allied Market Research

Reference : LI 173965

Number of Pages : 150

Report Format : PDF

Publisher Information :



Allied Market Research
Diligent Intelligence - Improved Growth

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

Table Of Contents for Ulcerative Colitis Market by Molecule Type (Biologics and Small Molecules), by Disease Type (Mild Ulcerative Colitis, Moderate Ulcerative Colitis, Severe Ulcerative Colitis), by Route of Administration (Oral and Injectables) - Global Opportunity Analysis and Industry Forecast, 2017-2023

- CHAPTER 1 INTRODUCTION1.1. REPORT DESCRIPTION1.2 KEY BENEFITS1.1.1. Secondary research1.1.2. Primary research1.1.3. Analyst tools & modelsCHAPTER 2 EXECUTIVE SUMMARY2.1. CXO PERSPECTIVECHAPTER 3 MARKET OVERVIEW3.1. MARKET DEFINITION AND SCOPE3.2. KEY FINDINGS3.2.1. Top investment pockets3.2.2. Top winning strategies3.3. PORTERS FIVE FORCES ANALYSIS3.4. CLINICAL TRIALS3.5. MARKET SHARE ANALYSIS, 20163.6. MARKET DYNAMICS3.6.1. Drivers3.6.1.1. Growing prevalence of ulcerative colitis disease3.6.1.2. Increase in R&D and investment by key players towards development of novel drug therapies3.6.1.3. Rise in government and non-government organization focus towards research in biologics3.6.2. Restraints3.6.2.1. Patent expiry of drugs3.6.2.2. Stringent government regulations towards approval of biosimilars3.6.3. Opportunities3.6.3.1. Untapped emerging economiesCHAPTER 4 ULCERATIVE COLITIS, BY DISEASE TYPE4.1. OVERVIEW4.1.1. Market size and forecast4.2. MILD ULCERATIVE COLITIS4.2.1. Key market trends4.2.2. Growth factors and opportunities4.2.3. Market size and forecast4.3. MODERATE ULCERATIVE COLITIS4.3.1. Key market trends4.3.2. Growth factors and opportunities4.3.3. Market size and forecast4.4. SEVERE ULCERATIVE COLITIS4.4.1. Key market trends4.4.2. Growth factors and opportunities4.4.3. Market size and forecastCHAPTER 5 ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE5.1. OVERVIEW5.1.1. Market size and forecast5.2. SMALL MOLECULES5.2.1. Market size and forecast5.3. BIOLOGICS5.3.1. Market size and forecastCHAPTER 6 ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION6.1. OVERVIEW6.1.1. Market size and forecast6.2. ORAL6.2.1. Market size and forecast6.3. INJECTABLES6.3.1. Market size and forecastCHAPTER 7 ULCERATIVE COLITIS MARKET, BY GEOGRAPHY7.1. OVERVIEW7.1.1. Market size and forecast7.2. NORTH AMERICA7.2.1. Key market trends7.2.2. Key growth factors and opportunities7.2.3. North America Market Size and Forecast for Ulcerative Colitis Market by Country7.2.4. North America Market Size and Forecast for Ulcerative Colitis Market by Disease Type7.2.5. North America Market Size and Forecast for Ulcerative Colitis Market by Molecule Type7.2.6. North America Market Size and Forecast for Ulcerative Colitis Market by Route of Administration7.2.6.1. U.S. Market Size and Forecast for Ulcerative Colitis Market by Disease Type7.2.6.2. U.S. Market Size and Forecast for Ulcerative Colitis Market by Molecule Type7.2.6.3. U.S. Market Size and Forecast for Ulcerative Colitis Market by Route of Administration7.2.6.4. Canada Market Size and Forecast for Ulcerative Colitis Market by Disease Type7.2.6.5. Canada Market Size and Forecast for Ulcerative Colitis Market by Molecule Type7.2.6.6. Canada Market Size and Forecast for Ulcerative Colitis Market by Route of Administration7.2.6.7. Mexico Market Size and Forecast for Ulcerative Colitis Market by Disease Type7.2.6.8. Mexico Market Size and Forecast for Ulcerative Colitis Market by Molecule Type7.2.6.9. Mexico Market Size and Forecast for Ulcerative Colitis Market by Route of Administration7.3. EUROPE7.3.1. Key market trends7.3.2. Key growth factors and opportunities7.3.3. Europe Market Size and Forecast for Ulcerative Colitis Market by Country7.3.4. Europe Market Size and Forecast for Ulcerative Colitis Market by Disease Type7.3.5. Europe Market Size and Forecast for Ulcerative Colitis Market by Molecule Type7.3.6. Europe Market Size and Forecast for Ulcerative Colitis Market by Route of Administration7.3.6.1. Germany Market Size and Forecast for Ulcerative Colitis Market by Disease Type7.3.6.2. Germany Market Size and Forecast for Ulcerative Colitis Market by Molecule Type7.3.6.3. Germany Market Size and Forecast for Ulcerative Colitis Market by Route of Administration7.3.6.4. UK Market Size and Forecast for Ulcerative Colitis Market by Disease Type7.3.6.5. UK Market Size and Forecast for Ulcerative Colitis Market by Molecule Type7.3.6.6. UK Market Size and Forecast for Ulcerative Colitis Market by Route of Administration7.3.6.7. Italy Market Size and Forecast for Ulcerative Colitis Market by Disease Type7.3.6.8. Italy Market Size and Forecast for Ulcerative Colitis Market by Molecule Type7.3.6.9. Italy Market Size and Forecast for Ulcerative Colitis Market by Route of Administration7.3.6.10. France Market Size and Forecast for Ulcerative Colitis Market by Disease Type7.3.6.11. France Market Size and Forecast for Ulcerative Colitis

Market by Molecule Type7.3.6.12. France Market Size and Forecast for Ulcerative Colitis Market by Route of Administration7.3.6.13. Spain Market Size and Forecast for Ulcerative Colitis Market by Disease Type7.3.6.14. Spain Market Size and Forecast for Ulcerative Colitis Market by Molecule Type7.3.6.15. Spain Market Size and Forecast for Ulcerative Colitis Market by Route of Administration7.3.6.16. Rest of Europe Market Size and Forecast for Ulcerative Colitis Market by Disease Type7.3.6.17. Rest of Europe Market Size and Forecast for Ulcerative Colitis Market by Molecule Type7.3.6.18. Rest of Europe Market Size and Forecast for Ulcerative Colitis Market by Route of Administration7.4. ASIA-PACIFIC7.4.1. Key market trends7.4.2. Key growth factors and opportunities7.4.3. Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Country7.4.4. Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Disease Type7.4.5. Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Molecule Type7.4.6. Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Route of Administration7.4.6.1. Japan Market Size and Forecast for Ulcerative Colitis Market by Disease Type7.4.6.2. Japan Market Size and Forecast for Ulcerative Colitis Market by Molecule Type7.4.6.3. Japan Market Size and Forecast for Ulcerative Colitis Market by Route of Administration7.4.6.4. China Market Size and Forecast for Ulcerative Colitis Market by Disease Type7.4.6.5. China Market Size and Forecast for Ulcerative Colitis Market by Molecule Type7.4.6.6. China Market Size and Forecast for Ulcerative Colitis Market by Route of Administration7.4.6.7. India Market Size and Forecast for Ulcerative Colitis Market by Disease Type7.4.6.8. India Market Size and Forecast for Ulcerative Colitis Market by Molecule Type7.4.6.9. India Market Size and Forecast for Ulcerative Colitis Market by Route of Administration7.4.6.10. Australia Market Size and Forecast for Ulcerative Colitis Market by Disease Type7.4.6.11. Australia Market Size and Forecast for Ulcerative Colitis Market by Molecule Type7.4.6.12. Australia Market Size and Forecast for Ulcerative Colitis Market by Route of Administration7.4.6.13. South Korea Market Size and Forecast for Ulcerative Colitis Market by Disease Type7.4.6.14. South Korea Market Size and Forecast for Ulcerative Colitis Market by Molecule Type7.4.6.15. South Korea Market Size and Forecast for Ulcerative Colitis Market by Route of Administration7.4.6.16. Rest of Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Disease Type7.4.6.17. Rest of Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Molecule Type7.4.6.18. Rest of Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Route of Administration7.5. LAMEA7.5.1. Key market trends7.5.2. Key growth factors and opportunities7.5.3. LAMEA Market Size and Forecast for Ulcerative Colitis Market by Country7.5.4. LAMEA Market Size and Forecast for Ulcerative Colitis Market by Disease Type7.5.5. LAMEA Market Size and Forecast for Ulcerative Colitis Market by Molecule Type7.5.6. LAMEA Market Size and Forecast for Ulcerative Colitis Market by Route of Administration7.5.6.1. South Africa Market Size and Forecast for Ulcerative Colitis Market by Disease Type7.5.6.2. South Africa Market Size and Forecast for Ulcerative Colitis Market by Molecule Type7.5.6.3. South Africa Market Size and Forecast for Ulcerative Colitis Market by Route of Administration7.5.6.4. Saudi Arabia Market Size and Forecast for Ulcerative Colitis Market by Disease Type7.5.6.5. Saudi Arabia Market Size and Forecast for Ulcerative Colitis Market by Molecule Type7.5.6.6. Saudi Arabia Market Size and Forecast for Ulcerative Colitis Market by Route of Administration7.5.6.7. Israel Market Size and Forecast for Ulcerative Colitis Market by Disease Type7.5.6.8. Israel Market Size and Forecast for Ulcerative Colitis Market by Molecule Type7.5.6.9. Israel Market Size and Forecast for Ulcerative Colitis Market by Route of Administration7.5.6.10. Rest of LAMEA Market Size and Forecast for Ulcerative Colitis Market by Disease Type7.5.6.11. Rest of LAMEA Market Size and Forecast for Ulcerative Colitis Market by Molecule Type7.5.6.12. Rest of LAMEA Market Size and Forecast for Ulcerative Colitis Market by Route of AdministrationCHAPTER 8 COMPANY PROFILES8.1. PFIZER INC.8.1.1. Company overview8.1.2. Company snapshot8.1.3. Operating business segments8.1.4. Business performance8.1.5. Key strategic moves and developments8.2. JOHNSON & JOHNSON8.2.1. Company overview8.2.2. Company snapshot8.2.3. Operating business segments8.2.4. Business performance8.2.5. Key strategic moves and developments8.3. GLAXOSMITHKLINE PLC8.3.1. Company overview8.3.2. Company snapshot8.3.3. Operating business segments8.3.4. Business performance8.3.5. Key strategic moves and developments8.4. ELI LILLY AND CO.8.4.1. Company overview8.4.2. Company snapshot8.4.3. Operating business segments8.4.4. Business performance8.4.5. Key strategic moves and developments8.5. SANOFI AVENTIS A/S8.5.1. Company overview8.5.2. Company snapshot8.5.3. Operating business segments8.5.4. Business performance8.5.5. Key strategic moves and developments8.6. ASTRAZENECA PLC8.6.1. Company overview8.6.2. Company snapshot8.6.3. Operating business segments8.6.4. Business performance8.6.5. Key strategic moves and developments8.7. MERCK & CO. INC.8.7.1. Company overview8.7.2. Company snapshot8.7.3. Operating business segments8.7.4. Business performance8.7.5. Key strategic moves and developments8.8. ABBOTT LABORATORIES8.8.1. Company overview8.8.2. Company snapshot8.8.3. Operating business segments8.8.4. Business performance8.8.5. Key strategic moves and developments8.9. INDEX PHARMACEUTICALS HOLDING AB8.9.1. Company overview8.9.2. Company snapshot8.9.3. Operating business

segments8.9.4. Key strategic moves and developments8.10. AJINOMOTO PHARMACEUTICALS CO., LTD.8.10.1. Company overview8.10.2. Company snapshot8.10.3. Operating business segments8.10.4. Key strategic moves and developments

List Of Tables in Ulcerative Colitis Market by Molecule Type (Biologics and Small Molecules), by Disease Type (Mild Ulcerative Colitis, Moderate Ulcerative Colitis, Severe Ulcerative Colitis), by Route of Administration (Oral and Injectables) - Global Opportunity Analysis and Industry Forecast, 2017-2023

TABLE 1. GLOBAL ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2016-2023 (\$MILLION)

TABLE 2. GLOBAL ULCERATIVE COLITIS MARKET FOR MILD ULCERATIVE COLITIS DISEASE TYPE, BY REGION, 2016-2023 (\$MILLION)

TABLE 3. GLOBAL ULCERATIVE COLITIS MARKET FOR MODERATE ULCERATIVE COLITIS, BY REGION, 2016-2023 (\$MILLION)

TABLE 4. GLOBAL ULCERATIVE COLITIS MARKET FOR SEVERE ULCERATIVE COLITIS, BY REGION, 2016-2023 (\$MILLION)

TABLE 5. GLOBAL ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2016-2023 (\$MILLION)

TABLE 6. GLOBAL ULCERATIVE COLITIS MARKET FOR SMALL MOLECULES, BY REGION, 2016-2023 (\$MILLION)

TABLE 7. GLOBAL ULCERATIVE COLITIS MARKET FOR BIOLOGICS, BY TYPE, 2016-2023 (\$MILLION)

TABLE 8. GLOBAL ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 (\$MILLION)

TABLE 9. GLOBAL ULCERATIVE COLITIS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY REGION, 2016-2023 (\$MILLION)

TABLE 10. GLOBAL ULCERATIVE COLITIS MARKET FOR INJECTABLES ROUTE OF ADMINISTRATION, BY REGION, 2016-2023 (\$MILLION)

TABLE 11. ULCERATIVE COLITIS MARKET, BY REGION, 2016-2023 (\$MILLION)

TABLE 12. NORTH AMERICA ULCERATIVE COLITIS MARKET, BY COUNTRY, 2016-2023 (\$MILLION)

TABLE 13. NORTH AMERICA ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2016-2023 (\$MILLION)

TABLE 14. NORTH AMERICA ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2016-2023 (\$MILLION)

TABLE 15. NORTH AMERICA ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 (\$MILLION)

TABLE 16. U.S. MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 (\$MILLION)

TABLE 17. U.S. MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 (\$MILLION)

TABLE 18. U.S. MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 (\$MILLION)

TABLE 19. CANADA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-

2023 (\$MILLION)

TABLE 20. U.S. MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 (\$MILLION)

TABLE 21. CANADA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 (\$MILLION)

TABLE 22. MEXICO MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 (\$MILLION)

TABLE 23. MEXICO MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 (\$MILLION)

TABLE 24. MEXICO MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 (\$MILLION)

TABLE 25. EUROPE ULCERATIVE COLITIS MARKET, BY COUNTRY, 2016-2023 (\$MILLION)

TABLE 26. EUROPE ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2016-2023 (\$MILLION)

TABLE 27. EUROPE ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2016-2023 (\$MILLION)

TABLE 28. EUROPE ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 (\$MILLION)

TABLE 29. GERMANY MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 (\$MILLION)

TABLE 30. GERMANY MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 (\$MILLION)

TABLE 31. GERMANY MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 (\$MILLION)

TABLE 32. UK MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 (\$MILLION)

TABLE 33. UK MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 (\$MILLION)

TABLE 34. UK MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 (\$MILLION)

TABLE 35. ITALY MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 (\$MILLION)

TABLE 36. ITALY MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 (\$MILLION)

TABLE 37. ITALY MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 (\$MILLION)

TABLE 38. FRANCE MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 (\$MILLION)

TABLE 39. FRANCE MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 (\$MILLION)

TABLE 40. FRANCE MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 (\$MILLION)

TABLE 41. SPAIN MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 (\$MILLION)

TABLE 42. SPAIN MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 (\$MILLION)

TABLE 43. SPAIN MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 (\$MILLION)

TABLE 44. REST OF EUROPE MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 (\$MILLION)

TABLE 45. REST OF EUROPE MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 (\$MILLION)

TABLE 46. REST OF EUROPE MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 (\$MILLION)

TABLE 47. ASIA-PACIFIC ULCERATIVE COLITIS MARKET, BY COUNTRY, 2016-2023 (\$MILLION)

TABLE 48. ASIA-PACIFIC ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2016-2023 (\$MILLION)

TABLE 49. ASIA-PACIFIC ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2016-2023 (\$MILLION)

TABLE 50. ASIA-PACIFIC ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 (\$MILLION)

TABLE 51. JAPAN MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 (\$MILLION)

TABLE 52. JAPAN MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 (\$MILLION)

TABLE 53. JAPAN MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 (\$MILLION)

TABLE 54. CHINA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 (\$MILLION)

TABLE 55. CHINA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 (\$MILLION)

TABLE 56. CHINA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 (\$MILLION)

TABLE 57. INDIA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 (\$MILLION)

TABLE 58. INDIA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 (\$MILLION)

TABLE 59. INDIA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 (\$MILLION)

TABLE 60. AUSTRALIA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 (\$MILLION)

TABLE 61. AUSTRALIA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 (\$MILLION)

TABLE 62. AUSTRALIA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF

ADMINISTRATION, 2016-2023 (\$MILLION)

TABLE 63. SOUTH KOREA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 (\$MILLION)

TABLE 64. SOUTH KOREA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 (\$MILLION)

TABLE 65. SOUTH KOREA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 (\$MILLION)

TABLE 66. REST OF ASIA-PACIFIC MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 (\$MILLION)

TABLE 67. REST OF ASIA-PACIFIC MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 (\$MILLION)

TABLE 68. REST OF ASIA-PACIFIC MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 (\$MILLION)

TABLE 69. LAMEA ULCERATIVE COLITIS MARKET, BY COUNTRY, 2016-2023 (\$MILLION)

TABLE 70. LAMEA ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2016-2023 (\$MILLION)

TABLE 71. LAMEA ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2016-2023 (\$MILLION)

TABLE 72. LAMEA ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 (\$MILLION)

TABLE 73. SOUTH AFRICA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 (\$MILLION)

TABLE 74. SOUTH AFRICA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 (\$MILLION)

TABLE 75. SOUTH AFRICA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 (\$MILLION)

TABLE 76. SAUDI ARABIA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 (\$MILLION)

TABLE 77. SAUDI ARABIA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 (\$MILLION)

TABLE 78. SAUDI ARABIA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 (\$MILLION)

TABLE 79. ISRAEL MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 (\$MILLION)

TABLE 80. ISRAEL MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 (\$MILLION)

TABLE 81. ISRAEL MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 (\$MILLION)

TABLE 82. REST OF LAMEA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 (\$MILLION)

TABLE 83. REST OF LAMEA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 (\$MILLION)

TABLE 84. REST OF LAMEA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 (\$MILLION)

TABLE 85. PFIZER: COMPANY SNAPSHOT

TABLE 86. PFIZER: OPERATING SEGMENTS

TABLE 87. J&J: COMPANY SNAPSHOT

TABLE 88. J&J: OPERATING SEGMENTS

TABLE 89. GSK: COMPANY SNAPSHOT

TABLE 90. GSK: OPERATING SEGMENTS

TABLE 91. ELI: COMPANY SNAPSHOT

TABLE 92. ELI: OPERATING SEGMENTS

TABLE 93. SANOFI: COMPANY SNAPSHOT

TABLE 94. SANOFI: OPERATING SEGMENTS

TABLE 95. ASTRAZENECA: COMPANY SNAPSHOT

TABLE 96. ASTRAZENECA: OPERATING SEGMENTS

TABLE 97. MERCK: COMPANY SNAPSHOT

TABLE 98. MERCK: OPERATING SEGMENTS

TABLE 99. ABBOTT: COMPANY SNAPSHOT

TABLE 100. ABBOTT: OPERATING SEGMENTS

TABLE 101. INDEX: COMPANY SNAPSHOT

TABLE 102. INDEX: OPERATING SEGMENTS

TABLE 103. AJINOMOTO: COMPANY SNAPSHOT

TABLE 104. AJINOMOTO: OPERATING SEGMENTS

List Of Figures, Charts and Diagrams in Ulcerative Colitis Market by Molecule Type (Biologics and Small Molecules), by Disease Type (Mild Ulcerative Colitis, Moderate Ulcerative Colitis, Severe Ulcerative Colitis), by Route of Administration (Oral and Injectables) - Global Opportunity Analysis and Industry Forecast, 2017-2023

FIGURE 1. GLOBAL ULCERATIVE COLITIS MARKET, 2016-2023

FIGURE 2. SEGMENTATION OF GLOBAL ULCERATIVE COLITIS MARKET, 2016-2023

FIGURE 3. TOP INVESTMENT POCKETS IN GLOBAL ULCERATIVE COLITIS MARKET

FIGURE 4. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2017)

FIGURE 5. BARGAINING POWER OF BUYERS

FIGURE 6. BARGAINING POWER OF SUPPLIERS

FIGURE 7. THREAT OF NEW ENTRANTS

FIGURE 8. THREAT OF SUBSTITUTION

FIGURE 9. COMPETITIVE RIVALRY

FIGURE 10. RESTRAINTS AND DRIVERS: GLOBAL ULCERATIVE COLITIS MARKET

FIGURE 11. GLOBAL ULCERATIVE COLITIS MARKET: DISEASE TYPE

FIGURE 12. ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE

FIGURE 13. ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION

FIGURE 14. ULCERATIVE COLITIS MARKET, BY GEOGRAPHY

FIGURE 15. PFIZER: NET SALES, 2014-2017 (\$MILLION)

FIGURE 16. PFIZER: REVENUE BY SEGMENT, 2016 (%)

FIGURE 17. PFIZER: REVENUE BY GEOGRAPHY, 2016 (%)

FIGURE 18. J&J: NET SALES, 2014-2017 (\$MILLION)

FIGURE 19. J&J: REVENUE BY SEGMENT, 2016 (%)

FIGURE 20. J&J: REVENUE BY GEOGRAPHY, 2016 (%)

FIGURE 21. GSK: NET SALES, 2014-2017 (\$MILLION)

FIGURE 22. GSK: REVENUE BY SEGMENT, 2016 (%)

FIGURE 23. GSK: REVENUE BY GEOGRAPHY, 2016 (%)

FIGURE 26. ELI: NET SALES, 2014-2017 (\$MILLION)

FIGURE 27. ELI: REVENUE BY SEGMENT, 2016 (%)

FIGURE 28. ELI: REVENUE BY GEOGRAPHY, 2016 (%)

FIGURE 29. SANOFI: NET SALES, 2014-2017 (\$MILLION)

FIGURE 30. SANOFI: REVENUE BY SEGMENT, 2016 (%)

FIGURE 31. SANOFI: REVENUE BY GEOGRAPHY, 2016 (%)

FIGURE 32. ASTRAZENECA: NET SALES, 2014-2017 (\$MILLION)

FIGURE 33. ASTRAZENECA: REVENUE BY SEGMENT, 2016 (%)

FIGURE 34. ASTRAZENECA: REVENUE BY GEOGRAPHY, 2016 (%)

FIGURE 35. MERCK: NET SALES, 2014-2017 (\$MILLION)

FIGURE 36. MERCK: REVENUE BY SEGMENT, 2016 (%)

FIGURE 37. MERCK: REVENUE BY GEOGRAPHY, 2016 (%)

FIGURE 38. ABBOTT: NET SALES, 2014-2017 (\$MILLION)

FIGURE 39. ABBOTT: REVENUE BY SEGMENT, 2016 (%)

FIGURE 40. ABBOTT: REVENUE BY GEOGRAPHY, 2016 (%)

How to Buy...

Ulcerative Colitis Market by Molecule Type (Biologics and Small Molecules), by Disease Type (Mild Ulcerative Colitis, Moderate Ulcerative Colitis, Severe Ulcerative Colitis), by Route of Administration (Oral and Injectables) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/123320>

Option 2 - Request a Proforma Invoice

Fill in the details below, and **Scan** this page **and email** it to us at bioportfolio97@gmail.com We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$2924** | Single User Price
- \$5024** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.